SCHEMBL2965523

SCHEMBL2965523

Cc1ccc2c(Nc3cc(OCc4ccc(F)cc4)ccc3Sc3ccc(O)cc3)ccnc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.55
AKT2 P31751 1/20 0.55
MAOB P27338 9/20 0.37
ACHE P22303 1/20 0.37
MAOA P21397 4/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
BLM P54132 2/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
PKM P14618 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
CASP6 P55212 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 1/20 0.35
PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2969828 0.91 PIM1 (0.55) PIM1AKT2MAOBACHEMAOA
SCHEMBL2954780 0.91 PIM1 (0.59) PIM1AKT2MAOBACHEMAOA
SCHEMBL2961613 0.91 PIM1 (0.60) PIM1AKT2MAOBACHEMAOA
SCHEMBL2969945 0.91 PIM1 (0.54) PIM1AKT2MAOBACHEMAOA
SCHEMBL2968742 0.88 PIM1 (0.42) PIM1AKT2MAOBMAOAMEN1
SCHEMBL810678 0.87 PIM1 (0.71) PIM1AKT2MAOBACHEMAOA
SCHEMBL2969836 0.86 PIM1 (0.55) PIM1AKT2MAOBMAOAMEN1
SCHEMBL2971513 0.86 PIM1 (0.54) PIM1AKT2MAOAMEN1KMT2A
SCHEMBL2963629 0.86 PIM1 (0.58) PIM1AKT2MAOBMAOA
SCHEMBL2964540 0.86 PIM1 (0.54) PIM1AKT2MAOBACHEMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAOB 3352/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAOB 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.